COMMUNIQUÉS West-GlobeNewswire

Amedisys Reports First Quarter 2025 Financial Results

23/04/2025 - 22:45

BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 [...]

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025

23/04/2025 - 23:00

BOCA RATON, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF) , a vertically integrated, multi-state cannabis operator, announced that it expects to [...]

Aptose Announces Auditor Not Standing for Re-Appointment

23/04/2025 - 23:00

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug [...]

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results

23/04/2025 - 23:01

CARLSBAD, California, April 23, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal [...]

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

23/04/2025 - 23:14

ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

23/04/2025 - 23:23

– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression – – Detailed [...]

OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025

23/04/2025 - 18:00

OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025 Présentations sur l’actif propriétaire Tedopi® et sur deux inhibiteurs de SIRPα développés en partenariat avec [...]

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025

23/04/2025 - 18:00

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025 Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer Ingelheim NANTES, France – April 23, 2025, [...]

EssilorLuxottica: Chiffre d’affaires T1 2025 - Forte croissance du chiffre d'affaires au premier trimestre

23/04/2025 - 18:00

Forte croissance du chiffre d'affaires au premier trimestre Chiffre d'affaires du Groupe en hausse de +8,1 % à taux de change courants et de +7,3 % à taux de change constants 1 au T1 Solide croissance des segments [...]

EssilorLuxottica: Q1 2025 Revenue - Strong revenue growth in the first quarter

23/04/2025 - 18:00

Strong revenue growth in the first quarter Group’s revenue up 8.1% at current and 7.3% at constant exchange rates 1 in Q1 Sound growth in both PS and DTC channels, with comparable-store sales 3 up 8% EMEA growing 10% at [...]

Artax Biopharma to present Phase 2a data on Nck modulator AX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting

23/04/2025 - 18:00

Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced topline results, [...]

La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue

23/04/2025 - 18:59

COMMUNIQUE DE PRESSE LA MOLECULE AB8939 OBTIENT LA DESIGNATION DE MEDICAMENT ORPHELIN DANS L’UNION EUROPEENNE AUPRES DE L’AGENCE EUROPEENNE DES MEDICAMENTS (EMA) DANS LE TRAITEMENT DE LA LEUCEMIE MYELOÏDE AIGUE Paris, [...]

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

23/04/2025 - 18:59

PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science SA (Euronext - [...]

John Flack Appointed CFO of Advanced Medical Pricing Solutions

23/04/2025 - 19:02

PHOENIX, April 23, 2025 (GLOBE NEWSWIRE) -- Advanced Medical Pricing Solutions (“AMPS”), a diversified healthcare technology company supporting transparent, affordable medical and prescription benefits, announced today [...]

Prime Biome Reviews (We Tried It for 115 Days) Here’s Our Month-by-Month Review, Unexpected Results, And Benefits!

23/04/2025 - 19:04

ALBANY, N.Y., April 23, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a dietary supplement designed to support skin and gut health by achieving microbial equilibrium in the body. It is loaded with probiotics for clear skin [...]

Pineal XT Reviews (WARNING) Is It Safe And Worth Trying? Understanding Its Natural Ingredients And Benefits!

23/04/2025 - 19:04

ALBANY, N.Y., April 23, 2025 (GLOBE NEWSWIRE) -- Pineal XT is a natural dietary capsule developed and designed to support cognitive functions. It blends in scientifically proven ingredients to enhance brain power, [...]

SynoGut Reviews (ALERT) Consumer Reports Reveal Unexpected Truths Behind Its Ingredients And Side Effects

23/04/2025 - 19:04

CANTON, Ohio, April 23, 2025 (GLOBE NEWSWIRE) -- SynoGut is a gut health support supplement that provides a natural way to support a healthy digestive system. The dietary formula is a combination of natural herbs, [...]

Science Translational Medicine Study Funded by the Bay Area Lyme Foundation Identifies FDA-approved Piperacillin as More Effective, Targeted Treatment for Lyme Disease

23/04/2025 - 20:00

An additional Science Translational Medicine study also funded by Bay Area Lyme Foundation uncovers how lingering bacterial cell wall molecules may contribute to chronic Lyme symptoms PORTOLA VALLEY, Calif., April 23, [...]

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

23/04/2025 - 14:05

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare [...]